Lindbrook Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Lindbrook Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-254	Closed	-$1.04K	–	2921
2024 Q2	$1.04K	Buy	254 +135	+113%	+$1.51K	﹤0.01%	2482
2024 Q1	$1.88K	Buy	+119	New	+$1.64K	﹤0.01%	2265
2023 Q4	–	Sell	-416	Closed	-$8.35K	–	2835
2023 Q3	$8.35K	Hold	416	–	–	﹤0.01%	1504
2023 Q2	$11.7K	Hold	416	–	–	﹤0.01%	1369
2023 Q1	$7.16K	Buy	416 +408	+5,100%	+$8.26K	﹤0.01%	1671
2022 Q4	$161	Sell	8 -89	-92%	-$1.91K	﹤0.01%	2765
2022 Q3	$2K	Buy	97 +12	+14%	+$328	﹤0.01%	2174
2022 Q2	$2K	Buy	+85	New	+$2.25K	﹤0.01%	2085

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Lindbrook Capital's ZNTL Position: Q3 2024 in Review

Lindbrook Capital sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2024, closing a stake of 254 shares — an estimated $1.04K sold.

Lindbrook Capital first reported a position in ZNTL in Q2 2022 and held it in 8 quarters. The position peaked at $11.7K in Q2 2023. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

Lindbrook Capital reported no remaining Zentalis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Lindbrook Capital sold 254 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $1.04K.
Lindbrook Capital first reported a position in Zentalis Pharmaceuticals in Q2 2022 and held it in 8 quarters.
Lindbrook Capital's Zentalis Pharmaceuticals position peaked at $11.7K in Q2 2023.
136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on Lindbrook Capital's 13F filing for Q3 2024, filed 1 Nov 2024.